Future Oncology
Volume 19, 2023 - Issue 2
Open access
5,159
Views
7
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy
Robert J Motzer1 Memorial Sloan Kettering Cancer Center,New York,NY 10065,USACorrespondence[email protected]
https://orcid.org/0000-0001-6925-2327View further author information
Manuela Schmidinger2 Medical University of Vienna,Vienna,1090,AustriaView further author information
, Masatoshi Eto3 Kyushu University Hospital,Fukuoka,812-8582,JapanView further author information
, Cristina Suarez4 Medical Oncology,Vall d’Hebron Institute of Oncology (VHIO),Vall d’Hebron University Hospital,Vall d’Hebron Barcelona Hospital Campus,Barcelona,08035,SpainView further author information
, Robert Figlin5 Cedars-Sinai Medical Center,Los Angeles,CA 90048,USAView further author information
, Yanfang Liu6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
, Rodolfo Perini6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
, Yayan Zhang6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
& Daniel YC Heng7 Tom Baker Cancer Centre,Calgary,AB T2N 4N2,CanadaView further author information
show all
Pages 113-121
|
Received 12 Aug 2022, Accepted 08 Dec 2022, Published online: 08 Feb 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.